{"success":true,"data":{"pressRelease":{"id":"17637","rtpr_id":"nPn3zXXnBa","ticker":"ADMA","exchange":"NASDAQ","all_tickers":["ADMA"],"title":"Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA","author":"PR Newswire","published_at":"2026-05-01T21:10:00.024Z","article_body":"Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA\n\nPR Newswire\n\nNEW YORK, May 1, 2026\n\nNEW YORK, May 1, 2026 /PRNewswire/ --\n\n(https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.html)\n\nWhy: Rosen Law Firm, a global investor rights law firm, announces an\ninvestigation of potential securities claims on behalf of shareholders of ADMA\nBiologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics\nmay have issued materially misleading business information to the investing\npublic.\n\nSo What: If you purchased ADMA Biologics securities you may be entitled to\ncompensation without payment of any out of pocket fees or costs through a\ncontingency fee arrangement. The Rosen Law Firm is preparing a class action\nseeking recovery of investor losses.\n\nWhat to do next: To join the prospective class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=57940\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678728-1&h=3863350642&u=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D57940&a=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D57940)\nor call Phillip Kim, Esq. toll-free at 866-767-3653 or email\ncase@rosenlegal.com (mailto:case@rosenlegal.com) for information on the class\naction.\n\nWhat is this about: On March 24, 2026, Investing.com published an article\nentitled \"ADMA Biologics shares plunge on short seller allegations.\" The\narticle stated that ADMA Biologics shares fell \"after short seller Culper\nResearch released a report alleging the company engaged in channel stuffing to\ninflate revenue growth.\"\n\nOn this news, ADMA Biologics stock fell 16.6% on March 24, 2026.\n\nWhy Rosen Law: We encourage investors to select qualified counsel with a track\nrecord of success in leadership roles. Often, firms issuing notices do not\nhave comparable experience, resources, or any meaningful peer recognition.\nMany of these firms do not actually litigate securities class actions. Be wise\nin selecting counsel. The Rosen Law Firm represents investors throughout the\nglobe, concentrating its practice in securities class actions and shareholder\nderivative litigation. Rosen Law Firm has achieved, at that time, the largest\never securities class action settlement against a Chinese Company. At the time\nRosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for\nnumber of securities class action settlements in 2017. The firm has been\nranked in the top 4 each year since 2013 and has recovered hundreds of\nmillions of dollars for investors. In 2019 alone the firm secured over $438\nmillion for investors. In 2020, founding partner Laurence Rosen was named by\nlaw360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been\nrecognized by Lawdragon and Super Lawyers.\n\nFollow us for updates on LinkedIn:\nhttps://www.linkedin.com/company/the-rosen-law-firm\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678728-1&h=2787511985&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm&a=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm)\n, on Twitter: https://twitter.com/rosen_firm\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678728-1&h=2621588709&u=https%3A%2F%2Ftwitter.com%2Frosen_firm&a=https%3A%2F%2Ftwitter.com%2Frosen_firm)\nor on Facebook: https://www.facebook.com/rosenlawfirm/\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678728-1&h=1820282312&u=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F&a=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F)\n.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\nContact Information:\n\nLaurence Rosen, Esq.\nPhillip Kim, Esq.\nThe Rosen Law Firm, P.A.\n275 Madison Avenue, 40th Floor\nNew York, NY 10016\nTel: (212) 686-1060\nToll Free: (866) 767-3653\nFax: (212) 202-3827\ncase@rosenlegal.com (mailto:case@rosenlegal.com)\nwww.rosenlegal.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678728-1&h=1554540152&u=https%3A%2F%2Fwww.rosenlegal.com%2F&a=www.rosenlegal.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-adma-biologics-inc-investors-to-inquire-about-securities-class-action-investigation--adma-302760296.html\n(https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-adma-biologics-inc-investors-to-inquire-about-securities-class-action-investigation--adma-302760296.html)\n\nSOURCE THE ROSEN LAW FIRM, P. A.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn3zXXnBa","title":"Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA","author":"PR Newswire","ticker":"ADMA","created":"2026-05-01T21:10:00.024Z","tickers":["ADMA"],"exchange":"NASDAQ","article_body":"Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA\n\nPR Newswire\n\nNEW YORK, May 1, 2026\n\nNEW YORK, May 1, 2026 /PRNewswire/ --\n\n(https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.html)\n\nWhy: Rosen Law Firm, a global investor rights law firm, announces an\ninvestigation of potential securities claims on behalf of shareholders of ADMA\nBiologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics\nmay have issued materially misleading business information to the investing\npublic.\n\nSo What: If you purchased ADMA Biologics securities you may be entitled to\ncompensation without payment of any out of pocket fees or costs through a\ncontingency fee arrangement. The Rosen Law Firm is preparing a class action\nseeking recovery of investor losses.\n\nWhat to do next: To join the prospective class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=57940\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678728-1&h=3863350642&u=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D57940&a=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D57940)\nor call Phillip Kim, Esq. toll-free at 866-767-3653 or email\ncase@rosenlegal.com (mailto:case@rosenlegal.com) for information on the class\naction.\n\nWhat is this about: On March 24, 2026, Investing.com published an article\nentitled \"ADMA Biologics shares plunge on short seller allegations.\" The\narticle stated that ADMA Biologics shares fell \"after short seller Culper\nResearch released a report alleging the company engaged in channel stuffing to\ninflate revenue growth.\"\n\nOn this news, ADMA Biologics stock fell 16.6% on March 24, 2026.\n\nWhy Rosen Law: We encourage investors to select qualified counsel with a track\nrecord of success in leadership roles. Often, firms issuing notices do not\nhave comparable experience, resources, or any meaningful peer recognition.\nMany of these firms do not actually litigate securities class actions. Be wise\nin selecting counsel. The Rosen Law Firm represents investors throughout the\nglobe, concentrating its practice in securities class actions and shareholder\nderivative litigation. Rosen Law Firm has achieved, at that time, the largest\never securities class action settlement against a Chinese Company. At the time\nRosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for\nnumber of securities class action settlements in 2017. The firm has been\nranked in the top 4 each year since 2013 and has recovered hundreds of\nmillions of dollars for investors. In 2019 alone the firm secured over $438\nmillion for investors. In 2020, founding partner Laurence Rosen was named by\nlaw360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been\nrecognized by Lawdragon and Super Lawyers.\n\nFollow us for updates on LinkedIn:\nhttps://www.linkedin.com/company/the-rosen-law-firm\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678728-1&h=2787511985&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm&a=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm)\n, on Twitter: https://twitter.com/rosen_firm\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678728-1&h=2621588709&u=https%3A%2F%2Ftwitter.com%2Frosen_firm&a=https%3A%2F%2Ftwitter.com%2Frosen_firm)\nor on Facebook: https://www.facebook.com/rosenlawfirm/\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678728-1&h=1820282312&u=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F&a=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F)\n.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\nContact Information:\n\nLaurence Rosen, Esq.\nPhillip Kim, Esq.\nThe Rosen Law Firm, P.A.\n275 Madison Avenue, 40th Floor\nNew York, NY 10016\nTel: (212) 686-1060\nToll Free: (866) 767-3653\nFax: (212) 202-3827\ncase@rosenlegal.com (mailto:case@rosenlegal.com)\nwww.rosenlegal.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678728-1&h=1554540152&u=https%3A%2F%2Fwww.rosenlegal.com%2F&a=www.rosenlegal.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-adma-biologics-inc-investors-to-inquire-about-securities-class-action-investigation--adma-302760296.html\n(https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-adma-biologics-inc-investors-to-inquire-about-securities-class-action-investigation--adma-302760296.html)\n\nSOURCE THE ROSEN LAW FIRM, P. A.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-01T21:10:00.060091172Z","server_sent_at_ms":1777669800060},"received_at":"2026-05-01T21:10:00.117Z","source_url":"https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-adma-biologics-inc-investors-to-inquire-about-securities-class-action-investigation--adma-302753271.html"},"analysis":{"id":"12915","press_release_id":"17637","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Rosen Law Firm announced an investigation of potential securities claims on behalf of ADMA Biologics investors regarding allegations of misleading business information.\n\nThe investigation stems from a March 24 report by short seller Culper Research which accused the company of channel stuffing to inflate revenue growth.\n\nThe firm is encouraging affected shareholders to contact them regarding a prospective class action lawsuit seeking recovery of losses.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"ADMA Biologics may have issued materially misleading business information to the investing public","namedEntities":{"people":[{"name":"Phillip Kim","role":"Attorney"},{"name":"Laurence Rosen","role":"Founding Partner"}],"products":[],"companies":[{"name":"Rosen Law Firm","relationship":"plaintiff law firm"},{"name":"ADMA Biologics, Inc.","ticker":"ADMA","relationship":"target"},{"name":"Investing.com","relationship":"media source"},{"name":"Culper Research","relationship":"short seller"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by Rosen Law Firm. No new disclosure from the issuer; no certified class or settlement announced. This is a standard investigation announcement following a prior short-seller report."},"tickerRelevance":{"others":[],"primary":"ADMA"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"newsSource":"PR Newswire","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Rosen Law Firm announced an investigation of potential securities claims on behalf of ADMA Biologics investors regarding allegations of misleading business information.\n\nThe investigation stems from a March 24 report by short seller Culper Research which accused the company of channel stuffing to inflate revenue growth.\n\nThe firm is encouraging affected shareholders to contact them regarding a prospective class action lawsuit seeking recovery of losses.","key_figures":{},"named_entities":{"people":[{"name":"Phillip Kim","role":"Attorney"},{"name":"Laurence Rosen","role":"Founding Partner"}],"products":[],"companies":[{"name":"Rosen Law Firm","relationship":"plaintiff law firm"},{"name":"ADMA Biologics, Inc.","ticker":"ADMA","relationship":"target"},{"name":"Investing.com","relationship":"media source"},{"name":"Culper Research","relationship":"short seller"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-01T21:15:59.968Z","global_importance":15,"audience_relevance":10,"importance_components":{"newsSource":"PR Newswire","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":141944,"modelName":"glm-4.7"}}